B8686
(+)-N-3-Benzylnirvanol
≥98% (HPLC), powder, CYP2C19 inhibitor
동의어(들):
(5S)-5-Ethyl-5-phenyl-3-(phenylmethyl)-2,4-imidazolidinedione, 5-Ethyl-5-phenyl-3-(phenylmethyl)hydantoin
로그인조직 및 계약 가격 보기
모든 사진(3)
About This Item
실험식(Hill 표기법):
C18H18N2O2
CAS Number:
Molecular Weight:
294.35
MDL number:
UNSPSC 코드:
12161501
PubChem Substance ID:
NACRES:
NA.77
추천 제품
제품명
(+)-N-3-Benzylnirvanol, ≥98% (HPLC), powder
Quality Level
분석
≥98% (HPLC)
양식
powder
solubility
DMSO: >20 mg/mL
H2O: insoluble
저장 온도
2-8°C
SMILES string
CC[C@]1(NC(=O)N(Cc2ccccc2)C1=O)c3ccccc3
InChI
1S/C18H18N2O2/c1-2-18(15-11-7-4-8-12-15)16(21)20(17(22)19-18)13-14-9-5-3-6-10-14/h3-12H,2,13H2,1H3,(H,19,22)/t18-/m0/s1
InChI key
ZMZDHUHMXXALFX-SFHVURJKSA-N
애플리케이션
(+)-N-3-Benzylnirvanol may be used as a cytochrome P450 2C19 (CYP2C19) inhibitor in a comparison study to treat cocktail and individual substrates for the screening for potent cytochrome P450 (CYP) inhibition. It may also be used in comparative studies to investigate its potential as CYP and non-CYP selective inhibitors of CYP2C19 in suspended human hepatocytes.
생화학적/생리학적 작용
(+)-N-3-Benzyl-nirvanol is a potent selective CYP2C19 inhibitor.
(+)-N-3-Benzyl-nirvanol is a potent selective CYP2C19 inhibitor. CYP2C19 has a high frequency of drug resistance; highly polymorphic.
(+)-N-3-Benzylnirvanol serves as an inhibitor of cytochrome P450 2B6 (CYP2B6).
신호어
Warning
유해 및 위험 성명서
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Acute 1 - Eye Irrit. 2
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
개인 보호 장비
dust mask type N95 (US), Eyeshields, Gloves
가장 최신 버전 중 하나를 선택하세요:
시험 성적서(COA)
Lot/Batch Number
이미 열람한 고객
James P Driscoll et al.
Chemical research in toxicology, 20(10), 1488-1497 (2007-09-26)
The hypothesis that the psychological side effects associated with the anesthetic phencyclidine (PCP) may be caused by irreversible binding of PCP or its reactive metabolite(s) to critical macromolecules in the brain has resulted in numerous in vitro studies aimed at
Guru R Valicherla et al.
Xenobiotica; the fate of foreign compounds in biological systems, 49(12), 1396-1402 (2019-02-13)
1. A protocol has been developed and validated for the high-throughput screening of eight major human cytochrome P450 (CYP) isozymes inhibition (CYP 1A2, 2C9, 2C19, 2D6, 3A4, 2B6, 2C8 and 2E1) using an in vitro probe cocktail containing eight substrates
Marie-Lynn Cuypers et al.
Drug metabolism and disposition: the biological fate of chemicals, 48(11), 1121-1128 (2020-08-26)
Early assessment of metabolism pathways of new chemical entities guides the understanding of drug-drug interactions. Selective enzyme inhibitors are indispensable in CYP reaction phenotyping. The most commonly applied CYP2C19 inhibitor, omeprazole, lacks selectivity. Two promising alternatives, (+)-N-3-benzylnirvanol and (-)-N-3-benzylphenobarbital, are
Dustyn A Barnette et al.
Biochemical pharmacology, 170, 113661-113661 (2019-10-13)
Terbinafine N-dealkylation pathways result in formation of 6,6-dimethyl-2-hepten-4-ynal (TBF-A), a reactive allylic aldehyde, that may initiate idiosyncratic drug-induced liver toxicity. Previously, we reported on the importance of CYP2C19 and 3A4 as major contributors to TBF-A formation. In this study, we
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.